BBLG Bone Biologics Corp - Common Stock
NASDAQ · Biotechnology close Oct 2, 2026BBLG Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
BBLG Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
| Ex-date | Split | Type |
|---|---|---|
| June 10, 2025 | 1-for-6 | Reverse |
| Dec. 20, 2023 | 1-for-8 | Reverse |
| June 7, 2023 | 1-for-30 | Reverse |
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Not enough fundamentals data to compute this ratio group yet.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
Not enough fundamentals data to compute this ratio group yet.
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 14, 2026 | $-0.43 | $-0.40 | -8.1% |
| March 31, 2026 | May 14, 2026 | $-0.43 | $-0.55 | 21.9% |
| Dec. 31, 2025 | $-0.14 | $-0.35 | 59.6% | |
| Sept. 30, 2025 | $-0.37 | $-1.25 | 70.5% | |
| June 30, 2025 | $-1.33 | $-0.59 | -124.8% | |
| March 31, 2025 | $-1.92 | $-2.94 | 34.6% |
Institutional owners (13F) 4 filers · $36K total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 1 (+1 vs prior Q) | 1 (-2 vs prior Q) | 0 (-1 vs prior Q) | 1 (0 vs prior Q) | +22K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| CITADEL ADVISORS LLC | $32,714 | 23,879 | 90.22% | Shares |
| Tower Research Capital LLC (TRC) | $2,676 | 1,953 | 7.38% | Shares |
| CLEAR STREET LLC | $556 | 138 | 1.53% | Shares |
| SBI Securities Co., Ltd. | $315 | 230 | 0.87% | Shares |
Activists & 5%+ owners 3 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Don Hankey, Knight Insurance Company, Ltd. ×9 filings | March 29, 2023 | · | Initial filing | · | SEC |
| Amir Farrokh Heshmatpour, AFH Holding & Advisory, LLC | Aug. 8, 2008 | · | Initial filing | Passive investment | SEC |
| Amir Farrokh Heshmatpour 2) | April 8, 2008 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 20 insiders · 5 officers · 14 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Jeff Frelick | Chief Executive Officer | Jan. 8, 2026 A | 17,204 | 0 | 0 | $0 |
| Stephen R. La Neve | CEO & President | Feb. 16, 2018 A | · | 0 | 0 | $0 |
| Deina H Walsh | Chief Financial Officer | Jan. 8, 2026 A | 15,000 | 0 | 0 | $0 |
| Amir F Heshmatpour | President and Secretary | Aug. 7, 2008 J | 5,000,000 | 0 | 0 | $0 |
| William Jay Treat | Chief Technology Officer | March 14, 2016 A | · | 0 | 0 | $0 |
| Phillip Terry Meikle II | Director | June 4, 2025 A | · | 0 | 0 | $0 |
| Siddhesh Rajendra Angle | Director | June 4, 2025 A | · | 0 | 0 | $0 |
| Bruce Stroever | Director | June 4, 2025 A | · | 0 | 0 | $0 |
| Robert E. Gagnon | Director | June 4, 2025 A | · | 0 | 0 | $0 |
| Erick Lucera | Director | Sept. 18, 2023 A | · | 0 | 0 | $0 |
| Bret Hankey | Director | Jan. 2, 2020 P | 28,122,518 | 0 | 0 | $0 |
| John J Booth | Director | Jan. 1, 2019 A | 20,822 | 0 | 0 | $0 |
| Jim Delshad | Director | Jan. 1, 2018 A | 40,822 | 0 | 0 | $0 |
| Steve B Warnecke | Director | Dec. 31, 2015 G | 0 | 0 | 0 | $0 |
| George A Oram | Director | Dec. 28, 2015 A | 40,822 | 0 | 0 | $0 |
| William F Coffin | Director | Dec. 28, 2015 A | 40,822 | 0 | 0 | $0 |
| Benjamin Wu | Director | Dec. 22, 2015 S | 970,991 | 0 | 0 | $0 |
| Chia B Soo | Director | Dec. 22, 2015 S | 2,982,804 | 0 | 0 | $0 |
| MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC. | 10% owner | Feb. 29, 2016 P | 11,640,096 | 0 | 0 | $0 |
| AFH Holding & Advisory, LLC | · | Aug. 6, 2014 J | 4,400,000 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
BBLG Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
1 analysts · 2026-09-29Mean target $12.20 +2466.3%
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.